Jefferies Group’s BridgeBio Pharma BBIO Stock Holding History

Jefferies Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-78,700	Closed	-$1.31M	–	1539
2021 Q4	$1.31M	Buy	+78,700	New	+$3.33M	0.01%	919
2020 Q3	–	Sell	-99,000	Closed	-$3.23K	–	1341
2020 Q2	$3.23K	Buy	+99,000	New	+$3.02M	0.04%	394

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jefferies Group's BBIO Position: Q1 2022 in Review

Jefferies Group sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 232,019 shares — an estimated $3.87M sold.

Jefferies Group first reported a position in BBIO in Q3 2019 and held it in 5 quarters. The position peaked at $13.4M in Q2 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

Jefferies Group reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 232,019 BridgeBio Pharma shares in Q1 2022, an estimated $3.87M.
Jefferies Group first reported a position in BridgeBio Pharma in Q3 2019 and held it in 5 quarters.
Jefferies Group's BridgeBio Pharma position peaked at $13.4M in Q2 2021.
178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.